

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

NCT06240754

Status	RECRUITING
Phase	Phase 2
Sponsor	Washington University School of Medicine
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (13)

- Unexplained cytopenia for at least 6 months. Cytopenia is defined as the presence of e1 blood count indexes below the following thresholds:
- Hgb ≤ 10 g/dL
- ANC $\leq 1.8 \times 10^9/L$
- Platelets $\leq 100 \times 10^9/L$
- IDH2 gene mutation (R140 or R172), performed locally, at a frequency $\geq 2\%$.
- ... and 8 more (see full listing online)

Exclusion (10)

- Indication of hematologic disease by bone marrow biopsy within 6 months of study entry.
- Evidence of disease progression from time of bone marrow biopsy to enrollment based on investigator review of symptoms and complete blood counts
- Active malignancy (defined as ≥ 1 cm disease on most recent CT scan in the past 6 months).
- Currently receiving therapy for solid tumor malignancy or received within the last 6 months.
- Currently receiving any other investigational agents.
- ... and 5 more (see full listing online)

Locations (1 total)

Washington University School of Medicine, St Louis, Missouri, United States

<https://clinicaltrials.gov/study/NCT06240754>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).